CINC424A2X01B Rollover Protocol

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

March 5, 2015

Primary Completion Date

September 16, 2027

Study Completion Date

September 16, 2027

Conditions
Primary MyelofibrosisPolycythemia VeraGraft Versus Host DiseaseAcute Myeloid LeukemiaThalassemia
Interventions
DRUG

ruxolitinib

ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study

DRUG

panobinostat

panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study

Trial Locations (98)

1413

Novartis Investigative Site, Sofia

1431

Novartis Investigative Site, Sofia

2010

Novartis Investigative Site, Darlinghurst

2013

Novartis Investigative Site, Soweto

2020

Novartis Investigative Site, Antwerp

2065

Novartis Investigative Site, St Leonards

3000

Novartis Investigative Site, Leuven

3128

Novartis Investigative Site, Box Hill

3168

Novartis Investigative Site, Clayton

3199

Novartis Investigative Site, Franston

4000

Novartis Investigative Site, Liège

4002

Novartis Investigative Site, Plovdiv

4029

Novartis Investigative Site, Herston

4032

Novartis Investigative Site, Debrecen

4102

Novartis Investigative Site, Wooloongabba

5041

Novartis Investigative Site, Bedford Park

5800

Novartis Investigative Site, Pleven

6000

Novartis Investigative Site, Perth

6001

Novartis Investigative Site, Kecskemét

7400

Novartis Investigative Site, Kaposvár

7800

Novartis Investigative Site, Cape Town

8000

Novartis Investigative Site, Bruges

10043

Novartis Investigative Site, Orbassano

10700

Novartis Investigative Site, Bangkok

20089

Novartis Investigative Site, Rozzano

20122

Novartis Investigative Site, Milan

20132

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

20246

Novartis Investigative Site, Hamburg

21100

Novartis Investigative Site, Varese

25123

Novartis Investigative Site, Brescia

27100

Novartis Investigative Site, Pavia

31008

Novartis Investigative Site, Pamplona

34093

Novartis Investigative Site, Istanbul

35100

Novartis Investigative Site, Izmir

37007

Novartis Investigative Site, Salamanca

38039

Novartis Investigative Site, Kayseri

39120

Novartis Investigative Site, Magdeburg

40138

Novartis Investigative Site, Bologna

50134

Novartis Investigative Site, Florence

52074

Novartis Investigative Site, Aachen

55131

Novartis Investigative Site, Mainz

60126

Novartis Investigative Site, Ancona

64718

Novartis Investigative Site, Monterrey

70124

Novartis Investigative Site, Bari

71013

Novartis Investigative Site, San Giovanni Rotondo

75475

Novartis Investigative Site, Paris

80138

Novartis Investigative Site, Napoli

89081

Novartis Investigative Site, Ulm

89124

Novartis Investigative Site, Reggio Calabria

90146

Novartis Investigative Site, Palermo

100730

Novartis Investigative Site, Beijing

125167

Novartis Investigative Site, Moscow

125284

Novartis Investigative Site, Moscow

129110

Novartis Investigative Site, Moscow

185019

Novartis Investigative Site, Petrozavodsk

197022

Novartis Investigative Site, Saint Petersburg

310003

Novartis Investigative Site, Hangzhou

411004

Novartis Investigative Site, Pune

1834111

Novartis Investigative Site, Afula

2540364

Novartis Investigative Site, Viña del Mar

7500922

Novartis Investigative Site, Santiago

8420383

Novartis Investigative Site, Santiago

9112001

Novartis Investigative Site, Jerusalem

M5G 1X8

Novartis Investigative Site, Toronto

01307

Novartis Investigative Site, Dresden

Novartis Investigative Site, Dresden

07740

Novartis Investigative Site, Jena

115 27

Novartis Investigative Site, Athens

265 04

Novartis Investigative Site, Pátrai

H-1097

Novartis Investigative Site, Budapest

H 6725

Novartis Investigative Site, Szeged

H-9700

Novartis Investigative Site, Szombathely

00161

Novartis Investigative Site, Roma

453-8511

Novartis Investigative Site, Nagoya

466 8560

Novartis Investigative Site, Nagoya

812-8582

Novartis Investigative Site, Fukuoka

060 8648

Novartis Investigative Site, Sapporo

259-1193

Novartis Investigative Site, Isehara

565 0871

Novartis Investigative Site, Suita

113-8677

Novartis Investigative Site, Bunkyo Ku

545-8586

Novartis Investigative Site, Osaka

113-0236

Novartis Investigative Site, Beirut

44-101

Novartis Investigative Site, Gliwice

50 367

Novartis Investigative Site, Wroclaw

1099-023

Novartis Investigative Site, Lisbon

1649-035

Novartis Investigative Site, Lisbon

0027

Novartis Investigative Site, Pretoria

0044

Novartis Investigative Site, Pretoria

06591

Novartis Investigative Site, Seoul

03080

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul

08003

Novartis Investigative Site, Barcelona

SE-14186

Novartis Investigative Site, Huddinge

SE 971 80

Novartis Investigative Site, Luleå

SE-221 85

Novartis Investigative Site, Lund

451 80

Novartis Investigative Site, Uddevalla

06230

Novartis Investigative Site, Ankara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY